130 related articles for article (PubMed ID: 34531687)
21. Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors.
Song P; Zhang J; Shang C; Zhang L
Sci Rep; 2019 Mar; 9(1):4278. PubMed ID: 30862891
[TBL] [Abstract][Full Text] [Related]
22. Subretinal macrophages produce classical complement activator C1q leading to the progression of focal retinal degeneration.
Jiao H; Rutar M; Fernando N; Yednock T; Sankaranarayanan S; Aggio-Bruce R; Provis J; Natoli R
Mol Neurodegener; 2018 Aug; 13(1):45. PubMed ID: 30126455
[TBL] [Abstract][Full Text] [Related]
23. [Value of serum carcinoembryonic antigen in prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor].
Xu CA; Su H; Liu JL; Li L; Zou HW
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):436-41. PubMed ID: 21875484
[TBL] [Abstract][Full Text] [Related]
24. Complement activation in patients with immune thrombocytopenic purpura according to phases of disease course.
Castelli R; Lambertenghi Delilliers G; Gidaro A; Cicardi M; Bergamaschini L
Clin Exp Immunol; 2020 Sep; 201(3):258-265. PubMed ID: 32515487
[TBL] [Abstract][Full Text] [Related]
25. Serum complement C1q level is associated with acute coronary syndrome.
Ni XN; Yan SB; Zhang K; Sai WW; Zhang QY; Ti Y; Wang ZH; Zhang W; Zheng CY; Zhong M
Mol Immunol; 2020 Apr; 120():130-135. PubMed ID: 32120180
[TBL] [Abstract][Full Text] [Related]
26. Effect of immunotherapy on the immune microenvironment in advanced recurrent cervical cancer.
Chen R; Yang W; Li Y; Cheng X; Nie Y; Liu D; Wang H
Int Immunopharmacol; 2022 May; 106():108630. PubMed ID: 35189471
[TBL] [Abstract][Full Text] [Related]
27. Three complement component 1q genes from rock bream, Oplegnathus fasciatus: genome characterization and potential role in immune response against bacterial and viral infections.
Bathige SD; Whang I; Umasuthan N; Wickramaarachchi WD; Wan Q; Lim BS; Park MA; Lee J
Fish Shellfish Immunol; 2013 Nov; 35(5):1442-54. PubMed ID: 23994081
[TBL] [Abstract][Full Text] [Related]
28. Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer.
Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Oh ST; Kim JG; Choi MH; Lee MA
Cancer Res Treat; 2018 Jan; 50(1):283-292. PubMed ID: 28494536
[TBL] [Abstract][Full Text] [Related]
29. [Difference analysis of chemotherapy efficacy among different primary tumor sites in metastatic colorectal cancer].
Sun Z; Wang X; Jia J; Liu C; Zhang X; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Oct; 19(10):1119-1123. PubMed ID: 27781247
[TBL] [Abstract][Full Text] [Related]
30. Impact of treatment delay due to the pandemic of COVID-19 on the efficacy of immunotherapy in head and neck cancer patients.
Chen G; Wu Q; Jiang H; Li Z; Hua X; Hu X; Yu H; Xie C; Zhong Y
J Hematol Oncol; 2020 Dec; 13(1):174. PubMed ID: 33308264
[TBL] [Abstract][Full Text] [Related]
31. Serum C1q Concentration Positively Correlates with Erythrocyte Sedimentation Rate in Polymyositis/Dermatomyositis.
Li L; Chen J; Chen S; Liu C; Zhang F; Li Y
Ann Clin Lab Sci; 2019 Mar; 49(2):237-241. PubMed ID: 31028070
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors for response and survival in patients with metastatic melanoma receiving immunotherapy.
Keilholz U; Scheibenbogen C; Sommer M; Pritsch M; Geuke AM
Melanoma Res; 1996 Apr; 6(2):173-8. PubMed ID: 8791276
[TBL] [Abstract][Full Text] [Related]
33. Serum Complement C1q Activity Is Associated With Obstructive Coronary Artery Disease.
Guo S; Mao X; Li X; Ouyang H; Gao Y; Ming L
Front Cardiovasc Med; 2021; 8():618173. PubMed ID: 33996933
[No Abstract] [Full Text] [Related]
34. Pilot Study of CT-Based Radiomics Model for Early Evaluation of Response to Immunotherapy in Patients With Metastatic Melanoma.
Wang ZL; Mao LL; Zhou ZG; Si L; Zhu HT; Chen X; Zhou MJ; Sun YS; Guo J
Front Oncol; 2020; 10():1524. PubMed ID: 32984000
[No Abstract] [Full Text] [Related]
35. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
[TBL] [Abstract][Full Text] [Related]
36. Pre-Immunotherapy Contrast-Enhanced CT Texture-Based Classification: A Useful Approach to Non-Small Cell Lung Cancer Immunotherapy Efficacy Prediction.
Shen L; Fu H; Tao G; Liu X; Yuan Z; Ye X
Front Oncol; 2021; 11():591106. PubMed ID: 33968716
[No Abstract] [Full Text] [Related]
37. The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy.
Botticelli A; Cirillo A; Scagnoli S; Cerbelli B; Strigari L; Cortellini A; Pizzuti L; Vici P; De Galitiis F; Di Pietro FR; Cerbelli E; Ghidini M; D'Amati G; Della Rocca C; Mezi S; Gelibter A; Giusti R; Cortesi E; Ascierto PA; Nuti M; Marchetti P
Vaccines (Basel); 2020 Apr; 8(2):. PubMed ID: 32353934
[TBL] [Abstract][Full Text] [Related]
38. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
[TBL] [Abstract][Full Text] [Related]
39. Complement component 1Q (C1Q) upregulation in retina of murine, primate, and human glaucomatous eyes.
Stasi K; Nagel D; Yang X; Wang RF; Ren L; Podos SM; Mittag T; Danias J
Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):1024-9. PubMed ID: 16505037
[TBL] [Abstract][Full Text] [Related]
40. Expression of C1q in the serum of patients with non‑severe aplastic anemia, and its association with disease severity.
Ding S; Liu C; Li Y; Liu H; Liu Z; Chen T; Zhang T; Shao Z; Fu R
Mol Med Rep; 2019 Feb; 19(2):1194-1202. PubMed ID: 30569170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
